Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences

• Published in: Scientific reports Vol. 12; no. 1; p. 8701
• Main Authors: Yao, Shuyang, Meric-Bernstam, Funda, Hong, David, Janku, Filip, Naing, Aung, Piha-Paul, Sarina Anne, Tsimberidou, Apostolia Maria, Karp, Daniel, Subbiah, Vivek, Yap, Timothy Anthony, Ahnert, Jordi Rodon, Pant, Shubham, Dumbrava, Ecaterina E Ileana, Wathoo, Chetna, Campbell, Erick, Yu, Lihou, Yamamura, Yuko, Fu, Siqing
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 24.05.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 631/337; 631/67; 692/4028; Angiogenesis; Body mass index; Clinical Trials, Phase I as Topic; Cyclin E; Cyclin E - genetics; Gene Amplification; Humanities and Social Sciences; Humans; Medical records; Metastases; Middle Aged; multidisciplinary; Mutation; Neoplasms - genetics; Oncogene Proteins - genetics; p53 Protein; Patients; Retrospective Studies; Science; Science (multidisciplinary); Solid tumors; Survival; Tumors
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-12669-5

Cyclin E is frequently encoded by CCNE1 gene amplification in various malignancies. We reviewed the medical records of patients with solid tumors displaying CCNE1 amplification to determine the effect of this amplification for future therapeutic development. We reviewed the medical records of patients with advanced solid tumors harboring CCNE1 amplification who were seen at the phase I clinic between September 1, 2012, and December 31, 2019. Among 79 patients with solid tumors harboring CCNE1 amplification, 56 (71%) received phase 1 clinical trial therapy, 39 (49%) had 3 or more concurrent genomic aberrances, and 52 (66%) had a concurrent TP53 mutation. The median overall survival (OS) after patients’ initial phase I visit was 8.9 months and after their initial metastasis diagnosis was 41.4 months. We identified four factors associated with poor risk: age < 45 years, body mass index ≥ 25 kg/m 2 , presence of the TP53 mutation, and elevated LDH > upper limit of normal. In patients treated with gene aberration-related therapy, anti-angiogenic therapy led to significantly longer OS after their initial phase I trial therapy than those who did not: 26 months versus 7.4 months, respectively (P = 0.04). This study provided preliminary evidence that CCNE1 amplification was associated with frequent TP53 mutation and aggressive clinical outcomes. Survival benefit was observed in patients who received antiangiogenic therapy and gene aberration-related treatment, supporting the future development of a personalized approach to combine gene aberration-related therapy with antiangiogenesis for the treatment of advanced malignancies harboring CCNE1 amplification.